FENNEC PHARMACEUTICALS INC. FENC
Nasdaq · XNAS · stock · Biological Products, (No Diagnostic Substances)
Chart by TradingView
0/9
Piotroski F — financial health
-4.88
Altman Z″ — distress risk · distress
—
Dividend payout · no dividend
Financials (annual, from 10-K)
| FY | Revenue | Net income | Gross profit | Free cash flow | Equity |
|---|---|---|---|---|---|
| 2025 | $44.6M | -$9.7M | — | — | $35.5M |
| 2024 | $47.5M | -$436,000 | — | — | -$5.9M |
| 2023 | $21.3M | -$16.0M | $20.0M | — | -$11.6M |
| 2022 | $1.8M | -$23.7M | $1.4M | — | -$2.6M |
| 2021 | — | -$17.3M | — | — | $15.8M |
| 2020 | $200,000 | -$18.1M | — | — | $29.1M |
Why these scores methodology →
Piotroski F-score: 0/9
- Positive return on assets
- Positive operating cash flow
- Rising ROA
- Cash flow exceeds net income
- Lower long-term debt
- Rising current ratio
- No share dilution
- Rising gross margin
- Rising asset turnover
Altman Z″: -4.88 (distress)
- Working capital / assets 0.801
- Retained earnings / assets -3.252
- EBIT / assets -0.089
- Equity / liabilities 1.011
Source: SEC EDGAR filings · CIK 0001211583 · as of 2025-12-31. Figures are facts from filings plus Stocktoria's own computed scores — not investment advice.